Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2020 07:00 ET | Source: Immatics N.V.

Immatics beruft Biotech-Experten Eliot Forster in den Aufsichtsrat

Tübingen, Deutschland und Houston, Texas, 15. September 2020 – Immatics N.V. (NASDAQ: IMTX; „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die...
September 10, 2020 07:00 ET | Source: Immatics N.V.

Immatics veröffentlicht Update zu ACTengine®-Zelltherapieprogramm IMA204 gegen eine Tumor-Stroma-Zielstruktur

Tübingen, Deutschland und Houston, Texas, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Das ACTengine®-Zelltherapieprogramm IMA204 adressiert COL6A3 Exon 6, eine neuartige Zielstruktur, die im...
September 10, 2020 07:00 ET | Source: https://immatics.com/

Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment

Tuebingen, Germany and Houston, Texas, Sept. 10, 2020 (GLOBE NEWSWIRE) -- IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy...
September 03, 2020 07:00 ET | Source: Immatics N.V.

Immatics veröffentlicht Ergebnisse des zweiten Quartals 2020 sowie Informationen zur Geschäftsentwicklung

Tübingen, Deutschland und Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Abschluss der Fusion mit ARYA Life Science Acquisition Corp. sowie anschließende Börsennotierung an der NASDAQ im...
September 03, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Second Quarter 2020 Financial Results and Business Update

Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction...
August 18, 2020 07:00 ET | Source: Immatics N.V.

Immatics weitet klinisches Studienprogramm für adoptive Zelltherapien auf Europa aus

Tübingen, Deutschland und Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandeltDie deutsche...
August 18, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs

Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trialGerman regulatory agency,...
August 06, 2020 07:00 ET | Source: https://immatics.com/

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth

Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP...
July 09, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 09, 2020 (GLOBE NEWSWIRE) -- Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage...
July 02, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Completion of Business Combination and Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 02, 2020 (GLOBE NEWSWIRE) -- The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right